Can a chatbot help end HIV? new study tests digital tool in black MSM

NCT ID NCT05968755

Not yet recruiting Prevention Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study will test a chatbot designed to increase awareness and use of PrEP, a daily pill that prevents HIV, among Black men who have sex with men (MSM) in the Southern United States. About 145 participants will interact with the chatbot over 90 days, answering questions and receiving personalized PrEP information. The goal is to see if the chatbot can help more men learn about and start taking PrEP, potentially reducing HIV rates in this high-risk group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: chatbot
What this could lead to: If successful, this chatbot could become a low-cost tool to increase PrEP use and reduce HIV rates in a high-risk community.
What could go wrong: This is a small, early-stage trial with no control group, so results may not be generalizable. The chatbot's impact on actual HIV prevention is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV PREVENTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV PREVENTION PREP AWARENESS PREP UPTAKE

Contacts and locations

Locations

Care 4 U Community Health Center

Miami, Florida, 33127, United States
Community Care Resources of FL (CCRSFL)

Pembroke Pines, Florida, 33027, United States
NAESM, Inc

Atlanta, Georgia, 30318, United States
RAO Community Health

Charlotte, North Carolina, 28202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.